Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial...

Opus Genetics has announced a key regulatory milestone, securing a Special Protocol Assessment (SPA)...

Regeneron Pharmaceuticals has announced that its Phase 3 QUASAR trial evaluating EYLEA HD (afliberce...

Aurion Biotech has released topline data from its Phase 1/2 clinical trial (CLARA), evaluating AURN0...

FDA has cleared the investigational new drug (IND) application for VG801, ViGeneron’s novel gene the...

Viridian Therapeutics has announced positive topline results from the Phase 3 THRIVE-2 clinical tria...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued...

eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics (‘Coave’), has announced that ...

The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose pref...

Atsena Therapeutics has successfully completed dosing in Part A of the LIGHTHOUSE study, a Phase I/I...